{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:47:55Z","timestamp":1786704475720,"version":"build-2736575974"},"reference-count":33,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T00:00:00Z","timestamp":1332201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Racial differences in follicular lymphoma (FL) in the United States have not been investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The National LymphoCare Study is a multicenter, longitudinal, observational cohort study collecting data on treatment patterns and outcomes for patients with newly diagnosed FL in the United States between 2004 and 2007 without any predefined, study\u2010specific intervention. The authors investigated differences between white (W) patients, African American (AA) patients, and Hispanic (H) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Among 2744 enrolled patients, there were 95 (3%) AA patients, 125 (5%) H patients, and 2476 (90%) W patients. Compared with W patients, more AA and H patients were diagnosed at age &lt;45 years (<jats:italic>P<\/jats:italic> &lt; .0001). H patients more commonly were diagnosed with grade 3 FL compared with AA and W patients (29%, 13%, and 18%, respectively; <jats:italic>P<\/jats:italic> = .019) and more commonly received rituximab plus chemotherapy as initial therapy compared with W patients (66% vs 50%; <jats:italic>P<\/jats:italic> = .036), while AA patients less commonly received anthracyclines (49% vs 64% in W patients; <jats:italic>P<\/jats:italic> = .027). H and AA patients who received rituximab plus chemotherapy were less likely than W patients to receive maintenance rituximab (27% vs 31% vs 40%, respectively; <jats:italic>P<\/jats:italic> = .031). At a median follow\u2010up of 52 months, progression\u2010free survival was similar between AA and W patients but was longer in H patients, and there was no difference in overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>In the largest prospective cohort to date of AA and H patients with FL in the United States, AA and H patients were younger at presentation. Although racial differences in treatment patterns for FL were noted, additional follow\u2010up is needed to determine the impact of these differences on survival. Cancer 2012. \u00a9 2012 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.27513","type":"journal-article","created":{"date-parts":[[2012,3,21]],"date-time":"2012-03-21T22:41:43Z","timestamp":1332369703000},"page":"4842-4850","source":"Crossref","is-referenced-by-count":41,"title":["Racial differences in presentation and management of follicular non\u2010Hodgkin lymphoma in the United States"],"prefix":"10.1002","volume":"118","author":[{"given":"Chadi","family":"Nabhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Byrtek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20073"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.15.1240"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-013367"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-041863"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.503"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0021"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.16.2106"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24757"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2007.01.005"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/725219"},{"key":"e_1_2_6_16_2","article-title":"Racial differences in the presentation and outcomes of diffuse large B\u2010cell lymphoma in the United States [published online ahead of print December 22, 2010]","author":"Shenoy PJ","year":"2010","journal-title":"Cancer."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.07.002"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23914"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802455867"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.3322\/CA.2007.0010"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.1.25"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4061"},{"key":"e_1_2_6_23_2","first-page":"110","article-title":"Expert second opinion pathology review of lymphoma in the era of the World Health Organization classification [abstract]","author":"Matasar M","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0053"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.5858\/2004-128-863-ACEOFL"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm511"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq574"},{"key":"e_1_2_6_28_2","first-page":"110","article-title":"Correlates of treatment intensity for initial management of follicular lymphoma (FL) in the United States: report from the National LymphoCare Study (NLCS) [abstract]","author":"Link B","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0283"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_6_31_2","first-page":"114","article-title":"Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first\u2010line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]","author":"Rummel M","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp175"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-008-9147-4"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-009-9382-3"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.27513","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.27513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T23:59:23Z","timestamp":1760313563000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.27513"}},"subtitle":["Report from the National LymphoCare Study"],"short-title":[],"issued":{"date-parts":[[2012,3,20]]},"references-count":33,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1002\/cncr.27513"],"URL":"https:\/\/doi.org\/10.1002\/cncr.27513","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,20]]}}}